Evidence for Supplemental Treatments in Androgenetic Alopecia

July 2014 | Volume 13 | Issue 7 | Original Article | 809 | Copyright © July 2014


Shannon Famenini MD and Carolyn Goh MD

Department of Medicine, Division of Dermatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

table 1
standardized treatments with these therapies, their long-term efficacy and safety has not yet been determined. Long-term, multi-center studies are needed to assess these factors and compare them to standard FDA-approved treatments.

DISCLOSUREs

The authors have not declared any relevant conflicts.

References

  1. Gan DC, Sinclair RD.Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10(3):184-9.
  2. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med. 2002;4(22):1-11.
  3. Hamada K, Randall VA. Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness. Br J Dermatol. 2006;154(4):609-18.
  4. Olsen EA, Hordinsky M, Roberts JL, Whiting DA. Dermatologic Consortium for Women’s Health Female pattern hair loss. J Am Acad Dermatol 2002; 47:795.
  5. Yip L, Zaloumis S, Irwin D et al. Association analysis of estrogen receptor beta gene (ESR2) polymorphisms with female pattern hair loss. Br J Dermatol 2012; 166:1131–4.
  6. Mella JM, Perret MC, Manzotti M et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146(10):1141.
  7. Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126-1134.
  8. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152(3):466-73.
  9. Bender DA. Chapter 44. Micronutrients: Vitamins & Minerals. In: Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil P. eds. Harper‘s Illustrated Biochemistry, 29e. New York: McGraw-Hill; 2012.http://accessmedicine.mhmedical.com/content.aspx?bookid=389&Sectionid=40142524. Accessed February 13, 2014
  10. Zempleni J, Hassan YI, Wijeratne SS. Biotin and biotinidase deficiency. Expert Rev Endocrinol Metab. 2008;3(6):715-724
  11. Wolf B. Biotinidase Deficiency. GeneReviewsâ„¢ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013. 2000 Mar 24 [updated 2011 Mar 15].
  12. Arslan M, Vurucu S, Balamtekin N, et al. The effects of biotin supplementation on serum and liver tissue biotinidase enzyme activity and alopecia in rats which were administrated to valproic acid . Brain Dev. 2009 ;31(6):405-10.
  13. Castro-Gago M, Pérez-Gay L, Gómez-Lado C, et al. The influence of valproic acid and carbamazepine treatment on serum biotin and zinc levels and on biotinidase activity. J Child Neurol. 2011;26(12):1522-4.
  14. Yilmaz Y, Tasdemir HA, Paksu MS. The influence of valproic acid treatment on hair and serum zinc levels and serum biotinidase activity. Eur J Paediatr Neurol. 2009;13(5):439-43.
  15. Schulpis KH, Karikas GA, Tjamouranis J, et al. Low serum biotinidase activity in children with valproic acid monotherapy. Epilepsia. 2001;42(10):1359-62.
  16. Schulpis KH, Georgala S, Papakonstantinou ED, et al. The effect of isotretinoin on biotinidase activity. Skin Pharmacol Appl Skin Physiol. 1999;12(1-2):28-33
  17. Frigg M, Schulze J, Volker L. Clinical Study on the effect of biotin on skin conditions in dogs. Schweiz Arch Tierheilk. 1989. 131:621-625.
  18. Limat A, Suormala T, Hunziker T, et al. Proliferation and differentiation of cultured human follicular keratinocytes are not influenced by biotin. Arch Dermatol Res. 1996;288(1):31-8.
  19. Chardon K, Bach V, Telliez F, et al. Effect of caffeine on peripheral chemoreceptor activity in premature neonates: interaction with sleep stages. J Appl Physiol (1985). 2004;96(6):2161-6.
  20. Banner W Jr, Czajka PA. Acute caffeine overdose in the neonate. Am J Dis Child. 1980;134(5):495-8.
  21. Herman A, Herman AP Caffeine’s mechanisms of action and its cosmetic use. Skin Pharmacol Physiol. 2013;26(1):8-14.
  22. Fischer TW, Hipler UC, Elsner P. Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro . Int J Dermatol. 2007;46(1):27-35.
  23. Use of a caffeine shampoo for the treatment of male androgenetic alopecia. J Appl Cosmetol. 2010; 28: 153–163
  24. Lemoine P, Nir T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16(4):372-80.
  25. Kobayashi H, Kromminga A, DunlopTW et al. A role of melatonin in neuroectodermal-mesodermal interactions: the hair follicle synthesizes melatonin and expresses functional melatonin receptors. FASEB J. 2005;19:1710–1712.
  26. Fischer TW, Elsner P. The antioxidative potential of melatonin in the skin. Curr Probl Dermatol. 2001;29:165–174.
  27. Tan DX, Chen LD, Poeggeler B et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J. 1993;1:57-60.
  28. Reiter RJ, Tan DX, Poeggeler B et al. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann N Y Acad Sci. 1994;719:1–12.
  29. Allain D, Ravault JP, PanarettoBA et al. Effects of pinealectomy on photoperiodic control of hair follicle activity in the Limousine ram: possible relationship with plasma prolactin levels . J Pineal Res 1986;3:25–32.
  30. Foitzik K, Krause K, NixonAJ et al. Prolactin and its receptor are expressed in murine hair follicle epithelium, show hair cycle-dependent expression, and induce catagen. Am J Pathol. 2003;162:1611–1621.
  31. Foitzik K, Krause K, Conrad F et al. Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apop-tosis-driven hair follicle regression. Am J Pathol 2006;168:748–756.
  32. Fischer TW, FischerA, Knoll B et al. Melatonin in low doses enhances in vitro human hair follicle proliferation and inhibits hair growth in high doses. Arch Derm Res. 2000;292:147.
  33. Fischer TW. Trueb RM, Hanggi G, et al. Topical Melatonin for Treatment of Androgenetic Alopecia. Int J Trichology. 2012; 4(4): 236–245.
  34. Fischer TW, Burmeister G, Schmidt HW, et al. Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol. 2004;150(2):341-5.
  35. Thom E. Efficacy and tolerability of Hairgain in individuals with hair loss: a placebo-controlled, double-blind study. J Int Med Res. 2001;29(1):2-6.
  36. Glynis A. A Double-blind, Placebo-controlled Study Evaluating the Efficacy of an Oral Supplement in Women with Self-perceived Thinning Hair . J Clin Aesthet Dermatol. 2012;5(11):28-34.
  37. Saper RB, Rash R. Zinc: an essential micronutrient. Am Fam Physician. 2009;79(9):768-72.
  38. Yanagisawa H. Zinc deficiency and clinical practice--validity of zinc preparations. Yakugaku Zasshi. 2008;128(3):333-9.
  39. Alhaj E, Alhaj N, Alhaj NE. Diffuse alopecia in a child due to dietary zinc deficiency. Skinmed. 2007;6(4):199-200.
  40. Kil MS, Kim CW, Kim SS. Analysis of serum zinc and copper concentrations in hair loss. Ann Dermatol. 2013 Nov;25(4):405-9.
  41. Berger RS, Fu JL, Smiles KA, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003;149(2):354-62.

AUTHOR CORRESPONDENCE

Carolyn Goh MDcgoh@mednet.ucla.edu